Does prophylactic levosimendan reduce the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device in patients with reduced left ventricular ejection fraction undergoing cardiac surgery with cardiopulmonary bypass?
Prophylactic levosimendan does not improve short-term clinical outcomes in patients with reduced LVEF undergoing cardiac surgery with cardiopulmonary bypass.
Prophylactic levosimendan did not result in a rate of the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device that was lower than the rate with placebo among patients with a reduced left ventricular ejection fraction who were undergoing cardiac surgery with the use of cardiopulmonary bypass. (Funded by Tenax Therapeutics; LEVO-CTS ClinicalTrials.gov number, NCT02025621 .).
Mehta et al. (2017) studied this question.